Robert D. Evans Sells 40,000 Shares of Penumbra Inc (NYSE:PEN) Stock

Penumbra Inc (NYSE:PEN) EVP Robert D. Evans sold 40,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $89.89, for a total transaction of $3,595,600.00. Following the transaction, the executive vice president now directly owns 11,704 shares in the company, valued at $1,052,072.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Penumbra Inc (PEN) traded up $3.65 during trading hours on Thursday, reaching $91.90. The company had a trading volume of 180,581 shares, compared to its average volume of 247,603. Penumbra Inc has a 12-month low of $67.95 and a 12-month high of $116.35. The firm has a market capitalization of $3,120.00 and a P/E ratio of 437.62.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.07. Penumbra had a return on equity of 0.25% and a net margin of 0.28%. The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $79.17 million. During the same quarter last year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 24.9% compared to the same quarter last year. analysts expect that Penumbra Inc will post -0.15 EPS for the current year.

A number of hedge funds have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Penumbra by 10.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock worth $102,000 after purchasing an additional 114 shares during the period. Simplex Trading LLC boosted its holdings in Penumbra by 116.2% during the fourth quarter. Simplex Trading LLC now owns 1,911 shares of the company’s stock worth $179,000 after buying an additional 1,027 shares during the last quarter. Verition Fund Management LLC bought a new position in Penumbra during the second quarter worth about $213,000. Teacher Retirement System of Texas bought a new position in Penumbra during the third quarter worth about $214,000. Finally, Ameritas Investment Partners Inc. boosted its holdings in Penumbra by 10.8% during the second quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock worth $226,000 after buying an additional 250 shares during the last quarter. 71.71% of the stock is owned by hedge funds and other institutional investors.

Several analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Penumbra from a “hold” rating to a “sell” rating in a report on Wednesday. BMO Capital Markets upped their price target on shares of Penumbra from $96.00 to $117.00 and gave the company an “outperform” rating in a report on Wednesday, November 8th. Canaccord Genuity upped their price target on shares of Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Finally, JPMorgan Chase & Co. lowered shares of Penumbra from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. Penumbra currently has an average rating of “Hold” and an average target price of $111.50.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/11/penumbra-inc-pen-evp-sells-3595600-00-in-stock.html.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply